[go: up one dir, main page]

CR9582A - Metodos para purificar anticuerpos anti a beta - Google Patents

Metodos para purificar anticuerpos anti a beta

Info

Publication number
CR9582A
CR9582A CR9582A CR9582A CR9582A CR 9582 A CR9582 A CR 9582A CR 9582 A CR9582 A CR 9582A CR 9582 A CR9582 A CR 9582A CR 9582 A CR9582 A CR 9582A
Authority
CR
Costa Rica
Prior art keywords
methods
protein
binding
binding protein
present application
Prior art date
Application number
CR9582A
Other languages
English (en)
Inventor
Godavarti Ranganathan
Iskra Timothy
Original Assignee
Wyeth Corp
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Elan Pharma Int Ltd filed Critical Wyeth Corp
Publication of CR9582A publication Critical patent/CR9582A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente solicitud proporciona metodos para purificar proteinas de enlace AB que tiene una region Fc, por ejemplo anticuerpos anti-AB o fusiones de anticuerpo, al adsorber la proteina de enlace AB a un agente de enlace Fc, tal como por ejemplo, Proteina A o Proteina G, seguido por un lavado con un amortiguador de sal de cation divalente para retirar impurezas y subsiguiente recuperacion de la proteina de enlace AB adsorbida. La presente solicitud tambien caracteriza metodos para eludir la proteina de enlace AB purificada asi como la incorporacion de los metodos dentro de un tren de purificacion. Tambien se proporcionan equipos que comprenden componentes para llevar a cabo los metodos e instrucciones de uso.
CR9582A 2005-06-17 2007-12-07 Metodos para purificar anticuerpos anti a beta CR9582A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69182105P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
CR9582A true CR9582A (es) 2008-05-05

Family

ID=37433887

Family Applications (2)

Application Number Title Priority Date Filing Date
CR9576A CR9576A (es) 2005-06-17 2007-12-07 METODOS PARA PURIFICAR PROTEINAS QUE CONTIENE LA REGION Fc
CR9582A CR9582A (es) 2005-06-17 2007-12-07 Metodos para purificar anticuerpos anti a beta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR9576A CR9576A (es) 2005-06-17 2007-12-07 METODOS PARA PURIFICAR PROTEINAS QUE CONTIENE LA REGION Fc

Country Status (25)

Country Link
US (3) US7820799B2 (es)
EP (3) EP1896504B1 (es)
JP (2) JP5150488B2 (es)
KR (2) KR101247836B1 (es)
CN (3) CN101213211A (es)
AR (2) AR053633A1 (es)
AU (2) AU2006261185B2 (es)
BR (2) BRPI0611599A2 (es)
CA (2) CA2611815A1 (es)
CR (2) CR9576A (es)
EA (2) EA201100177A1 (es)
EC (1) ECSP088086A (es)
ES (2) ES2402650T3 (es)
IL (2) IL187642A (es)
MA (1) MA29609B1 (es)
MX (2) MX2007015952A (es)
MY (1) MY144484A (es)
NI (1) NI200700329A (es)
NO (2) NO20076056L (es)
NZ (1) NZ565044A (es)
RU (1) RU2415865C2 (es)
SG (1) SG162806A1 (es)
TW (2) TW200740839A (es)
WO (2) WO2006138737A2 (es)
ZA (2) ZA200710330B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
CN101027391A (zh) * 2004-10-05 2007-08-29 惠氏公司 用于改善重组蛋白质产生的方法和组合物
WO2006047340A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AR051528A1 (es) 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1896504B1 (en) * 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2046833T3 (pl) * 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
KR101770312B1 (ko) * 2006-08-28 2017-08-22 아레스 트레이딩 에스.에이. Ｆｃ­함유 단백질을 정제하는 방법
EP2061802A1 (en) * 2006-08-28 2009-05-27 Ares Trading S.A. Process for the purification of fc-fusion proteins
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
WO2008156622A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
RU2538709C2 (ru) * 2007-10-05 2015-01-10 Дженентек, Инк. Гуманизированное антитело
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
US20100233678A1 (en) * 2007-11-13 2010-09-16 Beadling Leslie C Tunable affinity ligands for the separation and detection of target substances
KR101247374B1 (ko) * 2008-06-26 2013-03-26 한국생명공학연구원 면역글로불린 Ｇ의 Ｆｃ 부위에 선택적으로 결합하는 신규펩타이드 및 그의 제조방법
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
AU2009307728B2 (en) * 2008-10-20 2014-12-11 Abbvie Inc. Antibodies that bind to IL-18 and methods of purifying the same
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
RU2520838C2 (ru) 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
AU2009314311B2 (en) 2008-10-29 2013-01-10 Ablynx N.V. Methods for purification of single domain antigen binding molecules
AR073997A1 (es) 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9631008B2 (en) 2008-12-22 2017-04-25 Hoffmann-La Roche Inc. Immunoglobulin purification
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
US9233906B2 (en) * 2009-12-31 2016-01-12 Group Novasep SAS Purification of succinic acid from the fermentation broth containing ammonium succinate
WO2011107518A1 (de) * 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Selektive anreicherung von antikörpern
ES2648264T3 (es) * 2010-03-10 2017-12-29 F. Hoffmann-La Roche Ag Procedimiento para la purificación de soluciones de inmunoglobulinas
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2014507649A (ja) * 2011-01-18 2014-03-27 バクスター・インターナショナル・インコーポレイテッド ヒト血液中の抗βアミロイド抗体の測定
AU2012236486B2 (en) * 2011-03-29 2016-06-23 Glaxosmithkline Llc Buffer system for protein purification
SG10201604554WA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US10221210B2 (en) * 2011-07-20 2019-03-05 Zepteon, Incorporated Polypeptide separation methods
BR112014009178A2 (pt) * 2011-10-19 2018-09-04 Roche Glycart Ag métodos, uso, receptor e invenção
US20150239991A1 (en) * 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
TW201509432A (zh) 2013-07-05 2015-03-16 Lab Francais Du Fractionnement 親和層析基質
IL320195A (en) 2013-09-13 2025-06-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
MX2016015893A (es) * 2014-06-02 2017-03-20 Lab Francais Du Fractionnement Produccion de fragmentos de fragmento cristalizable (fc).
JP6451118B2 (ja) * 2014-07-17 2019-01-16 東ソー株式会社 抗体の分離方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105175548B (zh) * 2015-08-13 2019-02-05 齐鲁制药有限公司 重组人血管内皮生长因子受体-抗体融合蛋白的纯化方法
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
CA2992420A1 (en) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
EP3337817B1 (en) * 2015-08-21 2021-09-15 F. Hoffmann-La Roche AG Method for the reduction of host cell proteins in affinity chromatography
EP3344643B1 (en) * 2015-09-04 2025-07-02 Qiagen Sciences LLC Methods for co-isolation of nucleic acids and proteins
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455241B1 (en) 2016-05-11 2022-02-23 Cytiva BioProcess R&D AB Method of cleaning and/or sanitizing a separation matrix
KR102579850B1 (ko) * 2016-07-22 2023-09-18 암젠 인크 Fc-함유 단백질의 정제 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN106519029B (zh) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 一种Aβ寡聚体抗体的制备工艺
WO2018170488A1 (en) * 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
JP2018167260A (ja) * 2017-03-29 2018-11-01 三菱ケミカル株式会社 イオン交換体の保存方法、生理活性物質の精製装置及び生理活性物質の精製方法
JP7097433B2 (ja) * 2017-08-17 2022-07-07 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
CA3084059A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CN111902720B (zh) 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
CN112313344A (zh) 2018-04-24 2021-02-02 凯杰科技有限公司 从复杂样品中分离核酸并去除抑制剂
US20220314142A1 (en) 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
CN112409477B (zh) * 2019-08-21 2022-11-08 广东菲鹏生物有限公司 IgM纯化方法
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN113968909A (zh) * 2020-07-22 2022-01-25 信达生物制药(苏州)有限公司 一种双特异性抗体的纯化方法
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0463151T3 (da) * 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5112952A (en) * 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
ES2293661T3 (es) * 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
JP2002514919A (ja) * 1997-04-04 2002-05-21 バイオサイト ダイアグノスティックス，インコーポレイテッド 多価ライブラリーおよびポリクローナルライブラリー
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
DZ3295A1 (fr) 2000-02-24 2001-08-30 Anticorps humanises sequestrant un peptide amyloide .beta.
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ATE420114T1 (de) 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
EP1519740A4 (en) 2001-08-17 2005-11-09 Lilly Co Eli FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
WO2003066662A2 (en) * 2002-02-05 2003-08-14 Genentech, Inc. Protein purification
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
US20040229330A1 (en) * 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005044856A2 (en) * 2003-10-27 2005-05-19 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
BRPI0417689A8 (pt) * 2003-12-17 2017-04-25 Elan Pharm Inc Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
DK1701968T3 (da) * 2003-12-17 2015-06-22 Wyeth Llc Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
EP1767217A1 (en) 2004-07-14 2007-03-28 Astellas Pharma Inc. Agent for promoting the recovery from dysfunction after the onset of central neurological disease
CN101027391A (zh) 2004-10-05 2007-08-29 惠氏公司 用于改善重组蛋白质产生的方法和组合物
AR051800A1 (es) 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
AR051528A1 (es) 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
CN101111264A (zh) 2005-01-28 2008-01-23 惠氏公司 稳定化的液体多肽制剂
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1896504B1 (en) 2005-06-17 2012-11-21 Wyeth LLC Methods of purifying fc region containing antibodies
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
WO2006138553A3 (en) 2007-02-22
JP2008543881A (ja) 2008-12-04
BRPI0611599A2 (pt) 2011-02-22
ES2402650T3 (es) 2013-05-07
WO2006138737A8 (en) 2007-12-13
MA29609B1 (fr) 2008-07-01
JP2008543868A (ja) 2008-12-04
CA2611816A1 (en) 2006-12-28
KR20080023315A (ko) 2008-03-13
TWI372763B (en) 2012-09-21
US20070072307A1 (en) 2007-03-29
US7825223B2 (en) 2010-11-02
KR101307614B1 (ko) 2013-09-13
IL187642A0 (en) 2008-03-20
HK1117174A1 (en) 2009-01-09
BRPI0611600A2 (pt) 2011-03-15
EP1896506B1 (en) 2013-01-02
TW200840821A (en) 2008-10-16
CA2611816C (en) 2014-05-27
AR053633A1 (es) 2007-05-09
AU2006259298B2 (en) 2012-06-14
WO2006138553A2 (en) 2006-12-28
BRPI0611600B1 (pt) 2021-04-13
MY144484A (en) 2011-09-30
RU2415865C2 (ru) 2011-04-10
AU2006261185B2 (en) 2012-02-16
NO20076082L (no) 2007-12-27
ECSP088086A (es) 2008-02-20
KR101247836B1 (ko) 2013-03-28
EP2388274A1 (en) 2011-11-23
MX2007015952A (es) 2008-03-07
WO2006138737A3 (en) 2007-03-22
TW200740839A (en) 2007-11-01
EP1896504A2 (en) 2008-03-12
AU2006259298A1 (en) 2006-12-28
US7820799B2 (en) 2010-10-26
CN104926938A (zh) 2015-09-23
NI200700329A (es) 2015-04-21
EP1896504B1 (en) 2012-11-21
MX2007015051A (es) 2008-01-18
NZ565044A (en) 2010-05-28
ZA200710330B (en) 2009-12-30
EA015148B1 (ru) 2011-06-30
EA200800083A1 (ru) 2008-06-30
BRPI0611600B8 (pt) 2021-05-25
JP5150488B2 (ja) 2013-02-20
NO20076056L (no) 2008-01-11
IL187683A0 (en) 2008-08-07
EA201100177A1 (ru) 2011-06-30
EP1896506A2 (en) 2008-03-12
AU2006261185A1 (en) 2006-12-28
CN101365722A (zh) 2009-02-11
CN104926938B (zh) 2019-06-04
CA2611815A1 (en) 2006-12-28
IL187683A (en) 2015-02-26
RU2007143162A (ru) 2009-08-10
SG162806A1 (en) 2010-07-29
IL187642A (en) 2014-08-31
US20110160437A1 (en) 2011-06-30
CR9576A (es) 2008-03-06
AR053632A1 (es) 2007-05-09
KR20080059371A (ko) 2008-06-27
ZA200710331B (en) 2009-04-29
US20070082367A1 (en) 2007-04-12
US8440799B2 (en) 2013-05-14
JP5270337B2 (ja) 2013-08-21
WO2006138737A2 (en) 2006-12-28
ES2405079T3 (es) 2013-05-30
CN101213211A (zh) 2008-07-02

Similar Documents

Publication Publication Date Title
CR9582A (es) Metodos para purificar anticuerpos anti a beta
AR086525A1 (es) Metodo de purificacion de anticuerpos
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
BRPI0608584B8 (pt) métodos de recuperar um produto purificado
ZA201903994B (en) Ion exchange membrane chromatography
BRPI0517973B8 (pt) métodos para purificar o fsh recombinante
BRPI0516682A (pt) meio de filtração e processo para filtrar matéria particulada
CR20120359A (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
BR112012024550A2 (pt) processo para purificação de proteínas dependentes de vitamina k tal como o fator de coagulação ix
MX2012001659A (es) Metodo para mejorar la remocion del virus en una purificacion de proteina.
WO2011104307A3 (en) Ligands for antibody purification by affinity chromatography
WO2007130535A3 (en) Novel protein fusion/tag technology
RU2018138445A (ru) Способ очистки белка
DK1937402T3 (da) Anvendelse af regenererbare sorbenter til fjernelse af svovl fra carbonhydrider
AR060686A1 (es) Purificacion de trombina
TH85814A (th) วิธีการทำให้แอนตี้ เอ เบต้า แอนติบอดี้บริสุทธิ์
JP5089924B2 (ja) ＩｇＭ型抗体の精製方法、ＩｇＭ型抗体認識抗原の吸着材
ZHOU et al. Purification of monoclonal antibody against PGRP and its activity for small cell lung cancer in vitro
CO2021009000A2 (es) Procedimiento de filtración del fibrinógeno
BRPI0604909A (pt) processo e sistema de criação de um manual
LI et al. Purification of Rabbit Anti-human RBBP10 Polyclonal Antibody
EP2129461A4 (en) Purification of immunoglobulins
EA200501217A1 (ru) Способ очистки белка семейства трансформирующих ростовых факторов
TH85813A (th) วิธีการในการทำให้เอฟซี รีเจียน (Fc Region) บริสุทธิ์ซึ่งประกอบด้วยโปรตีน
GEU20061264Y (en) Method for purification of benzine